Quris Technologies LTD.

Based in Israel, Quris Technologies LTD. specializes in innovative drug development solutions through its Bio-AI Clinical Prediction Platform, enhancing the efficiency of drug candidate evaluations for the pharmaceutical industry. Founded in 2019 and headquartered in Tel Aviv, Israel, Quris Technologies LTD. focuses on leveraging AI to predict drug safety and efficacy.

The company was founded by Isaac Bentwich and Yossi Haran, with Bentwich having a background in technology and healthcare. Quris has completed 3 deals, with the most recent being a Seed funding round in December 2022, which raised USD 9. 000 mn from lead investor SB Investment Advisers and others, bringing its total amount raised to USD 9. 000 mn.

Quris Technologies LTD specializes in drug development through its innovative Bio-AI Clinical Prediction Platform. This platform utilizes advanced machine-learning techniques to predict the safety and efficacy of drug candidates in human subjects, significantly reducing the high costs associated with clinical trial failures, which affect 89% of drug candidates. The core offering includes testing drug compounds on miniaturized Patients-on-a-Chip, enabling the generation of data that informs classification algorithms for drug safety predictions. Targeting the pharmaceutical industry, Quris serves clients ranging from biotech firms to large pharmaceutical companies, with a focus on markets in North America and Europe.

The company’s commitment to providing reliable drug safety predictions positions it uniquely in a competitive landscape where traditional methods have proven inadequate. Quris generates revenue through strategic partnerships and B2B collaborations with pharmaceutical companies and research organizations that seek to enhance their drug development processes. The company's business model involves structured agreements where clients engage Quris’ predictive technology to assess their drug candidates under a subscription or project-based pricing model. Clients pay for access to the Bio-AI Clinical Prediction Platform, with costs linked to the scale and complexity of the drug testing undertaken.

These transactions enable clients to minimize risks in drug development, ultimately fostering more efficient paths to market for their therapeutic candidates. In December 2022, Quris Technologies LTD. raised USD 9. 000 mn in Seed funding to hire more personnel and advance its Bio-AI platform and research and development.

The company aims to expand its market presence, particularly focusing on North American and European regions, and will leverage this funding to accelerate new product launches and enhance its service offerings. Specific timelines for new product developments are not detailed, but the funding will support planned innovations in their predictive technology.